Overview

Erector Spinae Plane Block in Post-herpetic Neuralgia

Status:
Completed
Trial end date:
2021-06-19
Target enrollment:
0
Participant gender:
All
Summary
This randomized clinical study will be carried out on 72 patients admitted to the pain clinic in Tanta University Hospitals with post-herpetic neuralgia. Cases presenting to the Pain Clinic with acute pain due to postherpetic neuralgia in thoracic and/or lumbar dermatomes with numerical rating scale (NRS) of 6 or more and they will be randomly divided, using the closed envelop method, into three equal groups. Group A (24 patients): Patients will be subjected to the routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol) and sham erector spinae plane block Group B (24 patients): Patients will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose) together with medical treatment. Group C (24 patients): Patients that will subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg)) together with medical treatment. Primary outcome will be the efficacy of pain relief Secondary outcome will be the frequency of pain and the consumption of analgesics.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tanta University
Collaborator:
Dr. Amr Arafa Albadry
Treatments:
Magnesium Sulfate
Criteria
Inclusion Criteria:

- Cases presenting to the Pain Clinic with acute pain due to postherpetic neuralgia in
thoracic and/or lumbar dermatomes with a numerical rating scale (NRS) of 6 or more.

Exclusion Criteria:

- Patients commenced on opioids for any other reason rather than postherpetic neuralgia

- Secondary bacterial infection at the site of injection

- Uncontrolled psychiatric illness

- Uncooperative patients

- Refusal to participate in the study

- Diagnosed or suspected coagulopathy

- Morbid Obese patients with BMI >50 kg/m2

- Known history of allergy to local anesthetics

- Platelet count less than 75,000/ cc